1. Rafeq R, Igneri LA. Infectious pulmonary diseases. Infect Dis Clin North Am. 2024; 38(1): 1-17.
2. Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet. 2021; 398(10303): 906-919.
3. Candel FJ, Salavert M, Basaras M, et al. Ten issues for updating in community-acquired pneumonia: An expert review. J Clin Med. 2023; 12(21): 6864.
4. File TM Jr, Ramirez JA. Community-acquired pneumonia. N Engl J Med. 2023; 389(7): 632-641.
5. Dillon K, Garnick B, Fortier M, et al. The management of infectious pulmonary processes in the emergency department: Pneumonia. Physician Assist Clin. 2023; 8(1): 123-137.
6. Tsoumani E, Carter JA, Salomonsson S, Stephens JM, Bencina G. Clinical, economic, and humanistic burden of community acquired pneumonia in Europe: A systematic literature review.
Expert Rev Vaccines. 2023; 22(1): 876-884.
7. Cavallazzi R, Furmanek S, Arnold FW, et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest. 2020; 158(3): 1008-1016.
8. Burillo A, Candel FJ, Canut-Blasco A. Value of syndromic panels in the management of severe community-acquired pneumonia. Rev Esp Quimioter. 2022; 35(Suppl 1): 15-20.
9. Decker BK, Forrester LA, Henderson DK. Management of unique pneumonias seen in the intensive care unit. Infect Dis Clin North Am. 2022; 36(4): 825-837.
10. Davis D, Thadhani J, Choudhary V, et al. Advancements in the management of severe community-acquired pneumonia: A comprehensive narrative review. Cureus. 2023; 15(10): e46893.
11. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and
Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7): e45-e67.
12. Washington L, O’Sullivan-Murphy B, Christensen JD, McAdams HP. Radiographic imaging of community-acquired pneumonia: A case-based review. Infect Dis Clin North Am. 2024; 38(1):
19-33.
13. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America / American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in
adults. Clin Infect Dis. 2007; 44(Suppl 2): S27-72.
14. Niederman MS, Torres A. Severe community-acquired pneumonia. Eur Respir Rev. 2022; 31(166): 220123.
15. Martin-Loeches I, Garduno A, Povoa P, Nseir S. Choosing antibiotic therapy for severe community-acquired pneumonia. Curr Opin Infect Dis. 2022; 35(2): 133-139.
16. Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J. 2023; 61(4): 2200735.
17. Seo H, Cha SI, Park J, et al. Clinical relevance of bronchiectasis in patients with community-acquired pneumonia. Am J Med Sci. 2023; 365(6): 502-509.
18. Cavallazzi R, Ramirez JA. Influenza and viral pneumonia. Infect Dis Clin North Am. 2024; 38(1): 183-212.
19. Cavallazzi R, Ramirez JA. How and when to manage respiratory infections out of hospital. Eur Respir Rev. 2022; 31(166): 220092.
20. Yamana H, Tsuchiya A, Horiguchi H, Fushimi K, Jo T, Yasunaga H. Microbiological findings in patients with community-acquired pneumonia: An analysis using the National Hospital Orga-
nization Clinical Data Archives. J Infect Chemother. (Baskıda).
21. Garin N, Marti C, Skali Lami A, Prendki V. Atypical pathogens in adult community-acquired pneumonia and implications for empiric antibiotic treatment: A narrative review. Microorganis-
ms. 2022; 10(12): 2326.
22. Miyashita N. Atypical pneumonia: Pathophysiology, diagnosis, and treatment. Respir Investig. 2022; 60(1): 56-67.
23. Barimani MJ. Legionella: An uncommon cause of community-acquired pneumonia. JAAPA. 2022; 35(10): 38-42.
24. Moffa MA, Rock C, Galiatsatos P, Gamage SD, Schwab KJ, Exum NG. Legionellosis on the rise: A scoping review of sporadic, community-acquired incidence in the United States. Epidemiol
Infect. 2023; 151: e133.
25. Febbo J, Revels J, Ketai L. Viral pneumonias. Infect Dis Clin North Am. 2024; 38(1): 163-182.
26. Boattini M, Charrier L, Almeida A, et al. Burden of primary influenza and respiratory syncytial virus pneumonia in hospitalised adults: Insights from a 2-year multi-centre cohort study (2017-
2018). Intern Med J. 2023; 53(3): 404-408.
27. Ruiz-Spinelli A, Waterer G, Rello J. Severe community-acquired pneumonia in the post COVID-19 era. Curr Opin Crit Care. 2023; 29(5): 400-406.
28. Cillóniz C, Pericàs JM, Rojas JR, Torres A. Severe infections due to respiratory viruses. Semin Respir Crit Care Med. 2022; 43(1): 60-74.
29. Pickens CI, Wunderink RG. Novel and rapid diagnostics for common infections in the critically ill patient. Infect Dis Clin North Am. 2024; 38(1): 51-63.
30. Barreto JV, Dias CC, Cardoso T. Does etiological investigation have an impact on the outcomes of community-acquired pneumonia? – A prospective cohort study. Eur J Intern Med. 2023; 108:
85-92.
31. Covington EW, Rufe A. Identification of risk factors for multidrug-resistant organisms in community-acquired bacterial pneumonia at a community hospital. J Pharm Pract. 2023; 36(2):
303-308.
32. Jin W, Liang R, Tian X, et al. Clinical features of psittacosis in 46 Chinese patients. Enferm Infecc Microbiol Clin (Engl Ed). 2023; 41(9): 545-548.
33. Miyashita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, Ishiura Y. Validation of JRS atypical pneumonia score in patients with community-acquired Chlamydia psittaci pneumonia. J Infect
Chemother. 2023; 29(9): 863-868.
34. Furman CD, Leinenbach A, Usher R, Elikkottil J, Arnold FW. Pneumonia in older adults. Curr Opin Infect Dis. 2021; 34(2): 135-141.
35. Gao CA, Pickens CI, Morales-Nebreda L, Wunderink RG. Clinical features of COVID-19 and differentiation from other causes of CAP. Semin Respir Crit Care Med. 2023; 44(1): 8-20.
36. Singh AP, Finkelstein M, Chung M, Bernheim A. Review of thoracic imaging manifestations of COVID-19 and other pathologic coronaviruses. Radiol Clin North Am. 2022; 60(3): 359-369.
37. Tubiana S, Epelboin L, Casalino E, et al. Effect of diagnosis level of certainty on adherence to antibiotics’ guidelines in ED patients with pneumonia: A post-hoc analysis of an interventional
trial. Eur J Emerg Med. 2023; 30(2): 102-109.
38. Ruiz-Gaviria R, Marroquin-Rivera A, Pardi MD, Ross RW. Adherence to use of blood cultures according to current national guidelines and their impact in patients with community acquired
pneumonia: A retrospective cohort. J Infect Chemother. 2023; 29(7): 646-653.
39. Brixey AG, Reddy R, Giovanni SP. Nonimaging diagnostic tests for pneumonia. Radiol Clin North Am. 2022; 60(3): 521-534.
40. Evans S, Jennerich AL, Azar MM, et al. Nucleic acid-based testing for noninfluenza viral pathogens with suspected community-acquired pneumonia. An official American Thoracic Society
Clinical Practice Guideline. Am J Respir Crit Care Med 2021; 203(9): 1070–1087.
41. Chen S, Hou C, Kang Y, Li D, Rong J, Li Z. Factors affecting hospital discharge outcomes in patients with community-acquired pneumonia: A retrospective epidemiological study (2014-2021).
Am J Med Sci. 2023; 366(2): 143-149.
42. Zaki HA, Hamdi Alkahlout B, Shaban E, et al. The battle of the pneumonia predictors – A comprehensive meta-analysis comparing the Pneumonia Severity Index (PSI) and the CURB-65 score
in predicting mortality and the need for ICU support. Cureus. 2023; 15(7): e42672.
43. İlhan B, Bozdereli Berikol G, Doğan H. The prognostic value of rapid risk scores among patients with community-acquired pneumonia: A retrospective cohort study. Wien Klin Wochenschr.
2023; 135(19-20): 507-516.
44. Menéndez R, Cilloniz C, España PP, et al. Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. Arch
Bronconeumol. 2020; 56(Suppl. 1): 1–10.
45. Lim WS, Smith DL, Wise MP, Welham SA; British Thoracic Society. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: How they fit
together. Thorax. 2015; 70(7): 698-700.
46. Mikasa K, Aoki N, Aoki Y, et al. JAID/JSC guidelines for the treatment of respiratory infectious diseases: The Japanese Association for Infectious Diseases/Japanese Society of Che-
motherapy – The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-Preparing Committee Respiratory Infectious Disease WG. J Infect Chemother. 2016; 22(7,
Suppl.): S1-S65.
47. Lee MS, Oh JY, Kang CI, et al. Guideline for antibiotic use in adults with community-acquired pneumonia. Infect Chemother. 2018; 50(2): 160-198.
48. Wiersinga WJ, Bonten MJ, Boersma WG, et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB)
and Dutch Association of Chest Physicians (NVALT). Neth J Med. 2018; 76(1): 4-13.
49. Sayıner A, Babayiğit C, eds. Erişkinlerde Toplumda Gelişen Pnömoniler Tanı ve Tedavi Uzlaşı Raporu 2021. Ankara: Türk Toraks Derneği, 2021.
50. Martin-Loeches I, Torres A. New guidelines for severe community-acquired pneumonia. Curr Opin Pulm Med. 2021; 27(3): 210-215.
51. Antibacterial drugs for community-acquired pneumonia. Med Lett Drugs Ther. 2021; 63(1616): 10-14.
52. Zhanel GG, Deng C, Zelenitsky S, et al. Lefamulin: A novel oral and intravenous pleuromutilin for the treatment of community-acquired bacterial pneumonia. Drugs. 2021; 81(2): 233-256.
53. Guz D, McNeil R, Buchrits S, Goshen S, Gafter-Gvili A, Avni T. Ceftriaxone 1 g versus 2 g per day, for the treatment of community-acquired pneumonia: A retrospective cohort study. Intern
Emerg Med. 2023; 18(7): 1919-1927.
54. Gentile I, Buonomo AR, Corcione S, et al. CEFTO-CURE study – CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy. Int J Antimicrob Agents. 2023; 62(1): 106817.
55. Greco Kinney A, Kovacic Scherrer N, Sarkar S, Jain P, Wen S, Hadique S. β-lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically
ill patients. J Antimicrob Chemother. 2023; 78(12): 2816-2823.
56. Choi SH, Cesar A, Snow TAC, Saleem N, Arulkumaran N, Singer M. Efficacy of doxycycline for mild-to-moderate community-acquired pneumonia in adults: A systematic review and me-
ta-analysis of randomized controlled trials. Clin Infect Dis. 2023; 76(4): 683-691.
57. Choi SH, Cesar A, Snow TAC, Saleem N, Arulkumaran N, Singer M. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with
community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2023; 62(3): 106905.
58. Gómez-Zorrilla S, Sendra E, Horcajada JP. A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia. Expert Rev Clin Pharmacol. 2022; 15(6): 671-
688.
59. Lee A, Lamb YN, Shirley M. Delafloxacin: A review in community-acquired pneumonia. Drugs. 2022; 82(8): 913-923.
60. Goto A, Komiya K, Umeki K, Hiramatsu K, Kadota JI. Impact of Pseudomonas aeruginosa coverage on the prognosis of elderly patients with community-acquired pneumonia. J Infect Che-
mother. 2023; 29(1): 55-60.
61. Melani AS, Croce S, Cassai L, et al. Systemic corticosteroids for treating respiratory diseases – Less is better, but… when and how is it possible in real life. Pulm Ther. 2023; 9(3): 329-344.
62. Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023; 388(21): 1931-1941.
63. Dequin PF, Ramirez JA, Waterer G. What’s new with glucocorticoids in severe community-acquired pneumonia? Intensive Care Med. 2023; 49(11): 1397-1399.
64. Saleem N, Kulkarni A, Snow TAC, Ambler G, Singer M, Arulkumaran N. Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia – A systematic review,
meta-analysis, and meta-regression of randomized control trials. Chest. 2023; 163(3): 484-497.
65. Guzzardella A, Motos A, Vallverdú J, Torres A. Corticosteroids in sepsis and community-acquired pneumonia. Med Klin Intensivmed Notfmed. 2023; 118(Suppl. 2): 86-92.
66. Chaudhuri D, Nei AM, Rochwerg B, et al. 2024 focused update: Guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit
Care Med. (Baskıda).
67. Póvoa P, Coelho L, Salluh J. When should we use corticosteroids in severe community-acquired pneumonia? Curr Opin Infect Dis. 2021; 34(2): 169-174.
68. Deshpande A, Klompas M, Guo N, et al. Intravenous to oral antibiotic switch therapy among patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2023; 77(2): 174-185.
69. Dinh A, Crémieux AC, Guillemot D. Short treatment duration for community-acquired pneumonia. Curr Opin Infect Dis. 2023; 36(2): 140-145.
70. Jung J, Cozzi F, Forrest GN. Using antibiotics wisely. Curr Opin Infect Dis. 2023; 36(6): 462-472.
71. Lawrence H, McKeever TM, Lim WS; British Thoracic Society. Readmission following hospital admission for community-acquired pneumonia in England. Thorax. 2023; 78(12): 1254-1261.